OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Biomarker

HBV status (HBsAg + anti-HBc serology)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBIO-HBV-STATUS
TypeBiomarker
Aliases
HBV serologyHBsAg / anti-HBcHepatitis B screeningHepatitis B virus statusСтатус HBV (HBsAg + анти-HBc серологія)
Statusreviewed 2026-04-26 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-AASLD-HCC-2023 SRC-NCCN-BCELL-2025

Biomarker Facts

Biomarker typeviral_serology
Measurement
MethodThree-marker screening before B-cell-depleting or anti-CD38 therapy: HBsAg (current infection), anti-HBc total (past or occult infection), anti-HBs (immunity). HBV-DNA quantitative PCR follows when HBsAg+ or anti-HBc+ to distinguish active vs resolved infection.
Unitscategorical: HBsAg+ | anti-HBc+/HBsAg- (occult) | naive | vaccinated
Related biomarkersBIO-HCV-STATUS BIO-HIV-STATUS

Notes

Mandatory pre-treatment screening for any regimen containing rituximab, obinutuzumab, daratumumab, isatuximab, blinatumomab, or other B-cell-depleting / plasma-cell-depleting agents (HBV reactivation risk well-documented; ASH/ASCO/AASLD all align). Rules engine consumes as boolean flag: HBsAg+ OR anti-HBc+ → RF-HBV-COINFECTION fires → forces entecavir prophylaxis (or tenofovir if entecavir resistance) before any cycle of CD20/CD38-targeted therapy. Wired into CHL, DLBCL, MM, SMZL, Burkitt 1L algorithms. Subtypes informally: - HBsAg+ (active or chronic): prophylaxis mandatory; consult hepatology - HBsAg- / anti-HBc+ (resolved or occult): prophylaxis still recommended for high-risk regimens (rituximab-containing); HBV-DNA monitoring acceptable for low-risk regimens - HBsAg- / anti-HBc- / anti-HBs+ (vaccinated): no prophylaxis - All-negative (naive): no prophylaxis; consider vaccination if multi-line therapy anticipated reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Used By

Algorithms

Biomarker

Indications

Questionnaires